Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

Choosing between a SPAC and an IPO is about cost of capital, certainty of outcome, timing and the investor base you want to ...

LB Pharma needed $350 million to advance a promising schizophrenia candidate at a time when the biotech markets were locked ...

SpaceX's planned 2026 IPO could be good news for space stocks -- but it will more likely be bad news.

Explore the top crypto presale for 2026? IPO Genie combines AI deal screening, a $1M raise, Redwood AI proof, plus 35% bonus ...

Discover how laddering strategies help investors manage risks in bonds and fixed-income products, and learn about its ...

Last year saw a phenomenal rise in the number of public listings, mergers and acquisitions in the world of crypto. As for 2026, the party is just getting started. This week, crypto custodian BitGo is ...

Why the IPO market took off in 2025. In this podcast, Motley Fool analysts Emily Flippen and Sanmeet Deo and contirubtor Jason Hall break down why the IPO market took off in 2025, which new listings ...

Agibank looks undervalued post-IPO at 5.6x forward earnings, targeting Brazil’s underbanked with fast growth. Click here to find out why AGBK is a Buy.

In this podcast, Motley Fool contributors Tyler Crowe, Matt Frankel, and Jon Quast discuss: Rocket Lab's test failure. SpaceX's IPO rumors and who could quickly follow. Investing advice when analyzing ...

Initial public offerings offer investors a fresh lens on the market and, in some cases, a chance to uncover overlooked opportunities. This year’s IPO market will be dominated by familiar names like ...

Discover how pitchbooks help investment firms sell their services. Learn about the types of pitchbooks and see real-world ...